Aclaris Therapeutics Stock Quote ACRS - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.15

Bid

1.14

Ask

1.20

Volume

0.00 Day's Range 0.00

0.5902 52 Week Range 6.98

Market Cap

82.046M

Previous Close

1.15

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

578,921

Shares Outstanding

71,344,557

Dividend Yield

PE Ratio

-0.93

Earnings Per Share (EPS)

-1.24

Revenue

31.25M

Net Profit

-88.48M

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.aclaristx.com

Headquarters

Wilmington, Delaware, USA

Founded

Aclaris Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACRS. The last closing price for Aclaris Therapeutics was $1.15. Over the last year, Aclaris Therapeutics shares have traded in a share price range of $ 0.5902 to $ 6.98.

Aclaris Therapeutics currently has 71,344,557 shares outstanding. The market capitalization of Aclaris Therapeutics is $82.05 million. Aclaris Therapeutics has a price to earnings ratio (PE ratio) of -0.93.

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.04	-3.36134453782	1.19	1.22	1.15	325788	1.16971597	CS
4	-0.05	-4.16666666667	1.2	1.22	1.15	248952	1.17537715	CS
12	0.05	4.54545454545	1.1	1.43	1.1	578921	1.25532809	CS
26	-0.01	-0.862068965517	1.16	1.43	0.9515	636162	1.21632714	CS
52	-5.49	-82.6807228916	6.64	6.98	0.5902	1894990	1.33001857	CS
156	-16.38	-93.4398174558	17.53	19.97	0.5902	1020144	5.36178762	CS
260	-0.24	-17.2661870504	1.39	30.375	0.5902	985409	7.7763623	CS

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	$ 0.15 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 63.87 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.93 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 9.75 (0.00%)	0
AACGATA Creativity Global	$ 0.5103 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.15 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 63.87 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.93 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 9.75 (0.00%)	0
AACGATA Creativity Global	$ 0.5103 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.15 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 63.87 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.93 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 9.75 (0.00%)	0
AACGATA Creativity Global	$ 0.5103 (0.00%)	0

Symbol

Price

Vol.